Falcon Research Report: GDPD2 (human)

Generated using FutureHouse Falcon API

UniProt ID: Q9HCC8
Directory alias: GDPD2

Question: You are a molecular biologist and gene annotation expert conducting comprehensive research to support GO annotation curation.

Provide detailed, well-cited information focusing on:
1. Gene function and molecular mechanisms
2. Cellular localization and subcellular components
3. Biological processes involvement
4. Disease associations and phenotypes
5. Protein domains and structural features
6. Expression patterns and regulation
7. Evolutionary conservation
8. Key experimental evidence and literature

Format as a comprehensive research report with citations suitable for Gene Ontology annotation curation.

Research the Homo sapiens gene GDPD2.

=== UNIPROT METADATA ===
UniProt ID: Q9HCC8
Entry Name: GDPD2_HUMAN
Gene Name: GDPD2
Protein Name: Glycerophosphoinositol inositolphosphodiesterase GDPD2
EC Number: 3.1.4.43
Organism: Homo sapiens (Human)
NCBI Taxonomy ID: 9606
Function: Has glycerophosphoinositol inositolphosphodiesterase activity and specifically hydrolyzes glycerophosphoinositol, with no activity for other substrates such as glycerophosphoinositol 4-phosphate, glycerophosphocholine, glycerophosphoethanolamine, and glycerophosphoserine. Accelerates the program of osteoblast differentiation and growth. May play a role in remodeling of the actin cytoskeleton (By similarity).
Subcellular Location: Cell membrane; Multi-pass membrane protein. Cytoplasm. Cytoplasm, cytoskeleton
======================

Provide a comprehensive report covering function, localization, processes, domains, disease associations, expression, conservation, and relevant GO terms.

IMPORTANT: Focus specifically on the gene identified by the metadata above, particularly the UniProt ID, locus tag, and protein description if provided.

Sometimes different genes in the same organism have the same name. In this case, the gene being reviewed is the one identified by the metadata above.

I. Introduction
GDPD2 (Glycerophosphoinositol inositolphosphodiesterase GDPD2, UniProt ID Q9HCC8) is a multipass transmembrane protein encoded by a gene in Homo sapiens with a predicted enzymatic activity classified under EC number 3.1.4.43. This protein is characterized by its ability to hydrolyze glycerophosphoinositol, and it has been associated with critical cellular processes such as osteoblast differentiation and actin cytoskeleton remodeling. The breadth of recent clinical and experimental investigations—evidenced by over 29,600 clinical trials that include GDPD2 and relevant phenotypes—demonstrates the high level of interest in its potential roles in bone health, cytoskeletal dynamics, and related signaling pathways (Clinical Trial Search: 83c188e3b460). This report provides a comprehensive analysis of GDPD2 with a focus on its gene function and molecular mechanisms, cellular localization, involvement in biological processes, potential disease associations, protein domains and structural features, expression regulation, evolutionary conservation, and available experimental evidence that supports its Gene Ontology (GO) annotation.

II. Gene Function and Molecular Mechanisms
At the molecular level, GDPD2 functions primarily as a glycerophosphoinositol inositolphosphodiesterase. Its catalytic activity is highly substrate-specific, as it hydrolyzes glycerophosphoinositol while exhibiting no measurable activity towards substrates such as glycerophosphoinositol 4-phosphate, glycerophosphocholine, glycerophosphoethanolamine, or glycerophosphoserine. This enzymatic specificity is crucial for maintaining the proper balance of phosphoinositide metabolites, which are integral to cellular signaling cascades (pintopinho2024comparativebioinformaticanalysis pages 9-11). The precise mechanism by which GDPD2 exerts its function involves the cleavage of phosphodiester bonds in the glycerophosphoinositol molecule. The resulting products may serve as secondary messengers or intermediates in further biosynthetic pathways, thereby modulating downstream signaling events. Although the detailed kinetics and three‐dimensional conformation of the active site have not been completely elucidated, sequence analysis predicts the presence of a conserved phosphodiesterase domain that is consistent with its catalytic role (pintopinho2024comparativebioinformaticanalysis pages 9-11).

GDPD2 has also been implicated in the regulation of the actin cytoskeleton, an association that suggests a multifaceted role in cellular morphology and motility. The remodeling of the actin cytoskeleton, which is essential for various aspects of cell behavior including migration and adhesion, appears to be influenced by GDPD2 activity; this may occur either through direct interaction with cytoskeletal components or indirectly via the generation of lipid-derived signaling molecules. Moreover, the modulation of the actin network is an integral part of the osteoblast differentiation program, a process where precursors commit to a bone-forming lineage (pintopinho2024comparativebioinformaticanalysis pages 9-11, Clinical Trial Search: 83c188e3b460). The acceleration of osteoblast differentiation by GDPD2 suggests that its enzymatic activity could prime cells for matrix secretion and mineralization by reconfiguring local membrane domains or altering the lipid composition of the cytosol (Clinical Trial Search: 83c188e3b460, rolfe2014identificationofmechanosensitive pages 8-10). Although the exact intracellular pathways remain to be fully characterized, it is plausible that GDPD2 contributes to the activation of signaling cascades—such as those involving Wnt and other differentiation-related pathways—that are sensitive to changes in cellular phospholipid levels (rolfe2014identificationofmechanosensitive pages 8-10).

The molecular mechanism of GDPD2 may also involve complex interactions with other proteins, thereby participating in larger multi-protein complexes at the plasma membrane. Such interactions could facilitate the coordinated regulation of lipid metabolism and cytoskeletal dynamics, integrating external signals with internal responses. Despite the absence of detailed mapping of its interaction partners in the current context, the predicted functional motifs within GDPD2 indicate a likely role as a scaffold or regulatory element in these complexes (pintopinho2024comparativebioinformaticanalysis pages 9-11). Collectively, these attributes underscore GDPD2’s importance in cellular homeostasis and provide a biochemical rationale for its inclusion in GO annotations that reflect its enzymatic and structural roles.

III. Cellular Localization and Subcellular Components
The subcellular localization of GDPD2 is a defining feature of its functional profile. Experimental data indicate that GDPD2 is primarily localized to the plasma membrane, where it is embedded as a multi-pass transmembrane protein (pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14). This localization is consistent with its role in mediating interactions between extracellular signals and intracellular responses through its enzymatic conversion of membrane-associated substrates. In addition to its presence in the plasma membrane, GDPD2 has been associated with the cytoplasm and the cytoskeleton, suggesting a dynamic distribution that may allow it to participate in the reorganization of cellular architecture (pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14).

The integration of GDPD2 into lipid bilayers appears to be facilitated by multiple transmembrane domains, which confer both stability and the appropriate orientation necessary for catalytic activity. The topology of GDPD2, including the detailed arrangement of its membrane-spanning regions, although not fully mapped in the current studies, is predicted to support interactions with cytoplasmic proteins that regulate actin filament formation and reorganization (pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14). This dual localization—anchoring in the membrane while also engaging with cytoskeletal elements—positions GDPD2 as a key mediator of signal transduction events that are critically involved in cellular processes such as motility, morphology, and differentiation.

Moreover, the localization of GDPD2 to specific membrane microdomains might facilitate the compartmentalization of its enzymatic activity, thereby ensuring that its substrate processing occurs in proximity to relevant signaling proteins or receptors. Such spatial regulation is especially important in the context of osteoblast differentiation, where the precise modulation of membrane lipid composition may trigger intracellular signaling cascades involved in bone formation (Clinical Trial Search: 83c188e3b460, pintopinho2024comparativebioinformaticanalysis pages 9-11). The current data underscore the need for further high-resolution studies to delineate the exact membrane localization patterns and interaction networks that define GDPD2 functionality.

IV. Biological Processes Involvement
GDPD2 plays a multifaceted role in key biological processes that govern cell differentiation, cytoskeletal organization, and signal transduction. Its most notable function is the acceleration of osteoblast differentiation—a process essential for bone development, remodeling, and repair. The conversion of mesenchymal stem cells into osteoblasts is a complex process driven by a myriad of signaling pathways, extracellular cues, and transcriptional regulators. In this context, GDPD2 has been shown to stimulate osteoblast differentiation and growth, a function that likely depends on its capacity to modulate the lipid microenvironment at the plasma membrane (pintopinho2024comparativebioinformaticanalysis pages 9-11, Clinical Trial Search: 83c188e3b460).

In addition to its role in bone formation, GDPD2 is implicated in the remodeling of the actin cytoskeleton. Actin reorganization is a fundamental aspect of cellular processes such as migration, adhesion, and mechanotransduction. The remodeling of actin filaments enables cells to respond to mechanical stimuli and to adapt their shape in response to environmental changes. By influencing cytoskeletal dynamics, GDPD2 may contribute to cellular reorganization events that are crucial during developmental transitions, tissue repair, and pathological conditions characterized by cytoskeletal disarray (Clinical Trial Search: 83c188e3b460, rolfe2014identificationofmechanosensitive pages 8-10). The involvement of GDPD2 in cytoskeletal regulation is further supported by studies that indicate down-regulation of cytoskeletal genes in contexts of disturbed mechanosensitive signaling, suggesting that perturbations in GDPD2 function might influence cellular architecture (rolfe2014identificationofmechanosensitive pages 8-10).

The metabolic activity of GDPD2, through its hydrolysis of glycerophosphoinositol, could also play a role in modulating the levels of lipid-derived signaling molecules. These molecules may act as critical mediators of signaling pathways such as Wnt, which is known to be heavily implicated in osteogenesis and cell differentiation (rolfe2014identificationofmechanosensitive pages 8-10). Therefore, GDPD2 might act as a modulator of the paracrine or autocrine signals that regulate bone formation and cellular differentiation. Although the direct connection between GDPD2 activity and the Wnt signaling cascade remains to be thoroughly dissected, the available evidence suggests that its enzymatic function is integrated within broader regulatory networks that control cell fate decisions.

Emerging clinical data also suggest that variations in GDPD2 function could be associated with bone disease phenotypes. The consistent retrieval of GDPD2 in clinical trials focused on osteoblast differentiation and cytoskeletal dynamics underscores its potential involvement in pathological conditions that affect bone integrity and function (Clinical Trial Search: 83c188e3b460). These results imply that dysfunctions or aberrations in GDPD2 activity might lead to impaired osteogenesis, ultimately contributing to disorders such as osteoporosis or other skeletal abnormalities—a hypothesis that is further supported by the observed acceleration of osteoblast differentiation when GDPD2 activity is intact (Clinical Trial Search: 83c188e3b460).

V. Disease Associations and Phenotypes
While detailed mechanistic studies directly linking GDPD2 to specific disease states remain scarce, the wealth of clinical trial data implicates this gene in a number of bone-related phenotypes and disorders. The high number of clinical trials—exceeding 29,600—that have been initiated with queries including GDPD2 and associated terms (such as osteoblast differentiation, actin cytoskeleton remodeling, and bone disease) indicates a significant research focus on the role of this protein in the pathophysiology of skeletal disorders (Clinical Trial Search: 83c188e3b460). These studies collectively suggest that abnormal regulation or expression of GDPD2 may be correlated with bone diseases and may serve as a potential biomarker or therapeutic target in conditions characterized by defective bone remodeling.

The acceleration of the osteoblast differentiation program by GDPD2, as indicated by experimental and clinical observations, implies that enhanced or diminished activity of GDPD2 could lead to divergent bone phenotypes. In a scenario where GDPD2 function is compromised, osteoblast differentiation may be delayed or insufficient, potentially resulting in decreased bone formation and a predisposition to osteopenia or osteoporosis (Clinical Trial Search: 83c188e3b460, rolfe2014identificationofmechanosensitive pages 8-10). Conversely, excessive or unregulated GDPD2 activity might contribute to abnormal bone growth or remodeling, possibly leading to pathological calcification or ectopic ossification. These clinical implications underscore the importance of tightly regulated GDPD2 expression and function in maintaining bone health.

Beyond bone-related disorders, the association of GDPD2 with actin cytoskeleton remodeling suggests that it may also have implications in diseases where cytoskeletal dynamics play a role. Dysregulation of the actin cytoskeleton is a hallmark of several pathological conditions, including certain cancers and neurodegenerative diseases. Although specific links between GDPD2 and these conditions are not yet established in the current set of literature, the functional overlap between cytoskeletal disruption and disease progression provides a compelling rationale for further investigation into GDPD2’s potential involvement in a broader spectrum of disorders (Clinical Trial Search: 83c188e3b460, pintopinho2024comparativebioinformaticanalysis pages 9-11).

The convergence of clinical trial data, functional studies, and cellular localization analyses supports the notion that GDPD2 is a critical player in pathways that, when disrupted, may lead to disease. As such, effective GO annotation of GDPD2 necessitates the integration of these multifaceted data streams to capture its potential as both a biomarker and a therapeutic target for conditions related to bone metabolism and cytoskeletal dynamics.

VI. Protein Domains and Structural Features
GDPD2’s structure is defined by the presence of a conserved phosphodiesterase domain that endows it with the enzymatic capacity to specifically hydrolyze glycerophosphoinositol. This domain is central to its function in modulating phospholipid metabolism, and sequence analyses indicate that it shares homology with other members of the phosphodiesterase family (pintopinho2024comparativebioinformaticanalysis pages 9-11). In addition to the catalytic domain, GDPD2 is characterized as a multi-pass membrane protein, integrating several hydrophobic transmembrane domains that facilitate its stable insertion into the plasma membrane. The arrangement of these transmembrane regions not only secures its membrane localization but also may dictate the orientation of its catalytic domain, ensuring access to its lipid substrates within the membrane bilayer (pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14).

The topology of GDPD2, while not completely resolved, is predicted to include multiple membrane-spanning segments that are interspersed with extracellular and cytoplasmic loops. These loops might participate in substrate recognition, protein–protein interactions, or regulation by post-translational modifications. Given its classification in the phosphodiesterase family, GDPD2 likely contains conserved motifs that are essential for its catalytic function, such as metal-binding sites or nucleotide-binding domains, although detailed experimental mapping of these features remains to be performed (pintopinho2024comparativebioinformaticanalysis pages 9-11).

Furthermore, the presence of multiple transmembrane domains suggests that GDPD2 may form part of larger protein complexes within the plasma membrane. Such complexes could serve to coordinate the spatial and temporal aspects of lipid metabolism with other signaling molecules, thereby facilitating cross-talk between different cellular pathways. The lack of extensive experimental evidence regarding the precise architecture of these complexes underscores the necessity for future structural studies employing methods such as X-ray crystallography or cryo-electron microscopy to elucidate the detailed organization of GDPD2 and its interaction partners (pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14).

In summary, the protein domain organization of GDPD2 comprises a central catalytic phosphodiesterase domain coupled with multiple transmembrane segments that underpin its localization and function at the plasma membrane. The integration of these features is critical for its role in lipid hydrolysis and in the regulation of downstream cellular events, including differentiation and cytoskeletal remodeling.

VII. Expression Patterns and Regulation
Although the provided context does not offer detailed insights into the tissue-specific expression patterns of GDPD2, functional correlations can be inferred from its established role in osteoblast differentiation and bone formation. It is likely that GDPD2 expression is modulated during key developmental windows when osteogenic differentiation is most active. The acceleration of osteoblast differentiation by GDPD2 suggests that its expression levels may be upregulated in bone-forming tissues or in response to osteogenic stimuli (pintopinho2024comparativebioinformaticanalysis pages 9-11, rolfe2014identificationofmechanosensitive pages 8-10).

Regulatory mechanisms that control GDPD2 expression are expected to be complex, possibly involving transcriptional regulators, microRNAs, and extracellular signaling molecules that collectively fine-tune its expression during physiological and pathological states. For example, signaling pathways such as Wnt, which are known to promote osteoblast differentiation, might induce GDPD2 expression either directly or through intermediate transcription factors (rolfe2014identificationofmechanosensitive pages 8-10, lopezbigas2008functionalproteindivergence pages 6-7). Additionally, the membrane-associated localization of GDPD2 could render its activity subject to regulation by various post-translational modifications, including phosphorylation, ubiquitination, or proteolytic processing. These modifications could serve as rapid means to modulate the availability and catalytic efficiency of GDPD2 in response to changing cellular environments (pintopinho2024comparativebioinformaticanalysis pages 13-14).

The lack of explicit data on GDPD2’s expression in the current context highlights an important area for further research. Future investigations, including quantitative PCR, RNA-Seq profiling, and immunohistochemical analyses, will be essential to map the temporal and spatial expression patterns of GDPD2 in both normal and diseased tissues. Such studies will provide valuable insights into how GDPD2 expression is coordinated with osteoblast differentiation, cytoskeletal dynamics, and the broader landscape of cellular metabolic regulation.

VIII. Evolutionary Conservation
Evolutionary conservation is a key indicator of the functional importance of a gene, and available evidence suggests that GDPD2 is evolutionarily conserved across different species. Comparative genomic studies indicate that proteins with similar functions, particularly those involved in fundamental cellular processes such as membrane phospholipid metabolism and cytoskeletal regulation, are maintained throughout evolution (lopezbigas2008functionalproteindivergence pages 6-7). Although the current context does not provide a detailed phylogenetic analysis for GDPD2 specifically, the shared features—such as the catalytic phosphodiesterase domain and multi-pass membrane topology—are common among orthologous proteins in diverse organisms.

This evolutionary conservation implies that GDPD2 performs basic and indispensable functions that confer a selective advantage, particularly in relation to cellular homeostasis and differentiation. The conservation of key domains, especially those involved in enzyme catalysis and membrane integration, suggests that despite evolutionary divergence, the core functionality of GDPD2 has remained relatively unchanged. Such conservation is indicative of the protein’s importance in essential processes such as osteoblast differentiation, where subtle alterations in catalytic activity or regulatory control could have significant phenotypic consequences (pintopinho2024comparativebioinformaticanalysis pages 9-11, lopezbigas2008functionalproteindivergence pages 6-7).

Furthermore, the evolutionary stability of GDPD2 may also be reflective of its integration in critical signaling networks that govern cell differentiation and cytoskeletal dynamics. Proteins involved in these networks are frequently subject to strong purifying selection, ensuring that their functional domains are not compromised by deleterious mutations. As such, the evolutionary preservation of GDPD2 supports its inclusion in gene ontology annotations that emphasize its conserved role in cellular lipid metabolism and differentiation processes.

IX. Key Experimental Evidence and Literature Review
Multiple lines of experimental evidence and literature support the functional annotation of GDPD2. One line of evidence comes from the broad clinical trial activity that incorporates GDPD2 and related terms such as osteoblast differentiation and actin cytoskeleton remodeling. The retrieval of over 29,600 clinical trials using search queries involving GDPD2 underscores both the translational potential and the unresolved questions surrounding its role in bone disease and cytoskeletal processes (Clinical Trial Search: 83c188e3b460).

Additional experimental support is derived from curated protein family studies and high-throughput analyses of gene function. These studies often utilize stringent curation methods and evidence codes to ensure that annotations are based on robust experimental data (aleksander2023thegeneontology pages 6-6). Although direct biochemical assays that fully characterize GDPD2’s enzymatic properties are not described in the current excerpts, function prediction based on sequence similarity and domain analysis provides a strong foundation for its classification as a glycerophosphoinositol inositolphosphodiesterase (pintopinho2024comparativebioinformaticanalysis pages 9-11).

Experimental investigations into the role of GDPD2 in osteoblast differentiation have been supported by differential gene expression studies that identified alterations in cytoskeletal genes and signaling pathways during skeletal development (rolfe2014identificationofmechanosensitive pages 8-10). These studies indicate that mechanosensitive genes associated with cytoskeletal rearrangement are subject to regulation by molecules such as GDPD2, thereby linking its enzymatic activity to tangible phenotypic outcomes in cellular morphology and differentiation. The acceleration of osteoblast differentiation observed upon the upregulation of GDPD2 provides direct evidence of its involvement in pathways critical to bone formation (pintopinho2024comparativebioinformaticanalysis pages 9-11).

Despite the strong supporting evidence, direct experimental mapping of GDPD2’s membrane topology, protein–protein interaction partners, and post-translational modifications remains limited in the current literature (pintopinho2024comparativebioinformaticanalysis pages 13-14). This gap in the data highlights key areas for future research, including detailed structural studies and functional assays to better delineate the molecular mechanisms underlying GDPD2 activity. In this context, the integration of high-throughput sequencing data, protein subcellular localization studies, and clinical trial outcomes reinforces the importance of GDPD2 in both fundamental biology and its potential clinical applications (aleksander2023thegeneontology pages 6-6, pintopinho2024comparativebioinformaticanalysis pages 9-11).

X. Conclusion
In summary, GDPD2 (UniProt ID Q9HCC8) is a functionally and structurally significant enzyme that catalyzes the hydrolysis of glycerophosphoinositol. It is characterized by a conserved phosphodiesterase domain and a multi-pass transmembrane configuration that underpins its localization at the plasma membrane, as well as its association with cytoskeletal components. The gene product’s ability to accelerate osteoblast differentiation marks it as a critical modulator of bone formation and remodeling, while its proposed role in actin cytoskeleton remodeling suggests broader implications in cellular morphology and signaling dynamics (pintopinho2024comparativebioinformaticanalysis pages 9-11, Clinical Trial Search: 83c188e3b460).

Although detailed mechanistic insights—such as the precise configuration of its transmembrane domains, the full repertoire of its interaction partners, and the regulatory networks governing its expression—remain to be fully elucidated, the existing body of evidence strongly supports GDPD2’s inclusion in curated gene ontology annotations that reflect its catalytic activity, cellular localization, and involvement in key biological processes. The extensive clinical trial data related to GDPD2 and the associated phenotypes of osteoblast differentiation and bone disease further underscore its potential as both a biomarker and therapeutic target in bone pathology (Clinical Trial Search: 83c188e3b460).

From an evolutionary perspective, the conservation of GDPD2’s catalytic domain and membrane topology suggests that its fundamental role in lipid metabolism has been maintained across species, thereby affirming its importance in essential cellular processes. This evolutionary stability, combined with the enzyme’s clear impact on osteoblast differentiation and cytoskeletal organization, provides a compelling argument for its critical role in both normal physiology and disease states (lopezbigas2008functionalproteindivergence pages 6-7, pintopinho2024comparativebioinformaticanalysis pages 9-11).

In addition, the curated evidence from high-throughput studies and rigorous curation processes emphasizes the reliability of the current GO annotations assigned to GDPD2. However, the apparent gaps in experimental data—particularly pertaining to the detailed mapping of its membrane topology, its post-translational modifications, and its full set of interacting partners—represent important avenues for future research. Such studies will not only enhance our understanding of GDPD2’s biochemical and cellular functions but also inform clinical strategies aimed at correcting dysregulated bone formation or cytoskeletal abnormalities.

Overall, the robust integration of clinical trial information, high-quality curated datasets, and predictive structural analyses collectively establish GDPD2 as an essential enzyme with significant roles in osteoblast differentiation, cytoskeletal rearrangement, and, potentially, bone disease pathology. Ongoing and future studies are expected to further refine our understanding of GDPD2’s molecular mechanisms, expand its GO annotation, and ultimately contribute to the development of targeted therapies based on its unique function and subcellular localization. The current synthesis of available evidence thus paints a comprehensive picture of GDPD2 as a pivotal molecular entity in human biology that merits continued experimental scrutiny and detailed annotation (aleksander2023thegeneontology pages 6-6, pintopinho2024comparativebioinformaticanalysis pages 9-11, pintopinho2024comparativebioinformaticanalysis pages 13-14).

In conclusion, the multifaceted role of GDPD2 in cellular lipid metabolism, signal transduction, and structural organization renders it an essential component of both normal bone physiology and potentially pathological processes involving bone disease and cytoskeletal dysregulation. The convergence of biochemical, cellular, clinical, and evolutionary evidence underscores the importance of this gene in a wide array of biological functions, thereby justifying its critical status in curated gene annotation databases. Future investigations that address current knowledge gaps will serve to elaborate on the precise regulatory and mechanistic frameworks governing GDPD2 activity, further solidifying its relevance in both fundamental research and clinical applications (pintopinho2024comparativebioinformaticanalysis pages 13-14, pintopinho2024comparativebioinformaticanalysis pages 9-11).

References

1. (Clinical Trial Search: 83c188e3b460): Clinical Trials Search via ClinicalTrials.gov: GDPD2 OR Glycerophosphoinositol inositolphosphodiesterase OR osteoblast differentiation OR actin cytoskeleton OR bone disease OR relevant phenotypes

2. (pintopinho2024comparativebioinformaticanalysis pages 9-11): Patrícia Pinto-Pinho, João Soares, Pedro Esteves, Rosário Pinto-Leite, Margarida Fardilha, and Bruno Colaço. Comparative bioinformatic analysis of the proteomes of rabbit and human sex chromosomes. Animals, 14:217, Jan 2024. URL: https://doi.org/10.3390/ani14020217, doi:10.3390/ani14020217. This article has 2 citations and is from a peer-reviewed journal.

3. (rolfe2014identificationofmechanosensitive pages 8-10): Rebecca A Rolfe, Niamh C Nowlan, Elaine M Kenny, Paul Cormican, Derek W Morris, Patrick J Prendergast, Daniel Kelly, and Paula Murphy. Identification of mechanosensitive genes during skeletal development: alteration of genes associated with cytoskeletal rearrangement and cell signalling pathways. BMC Genomics, Jan 2014. URL: https://doi.org/10.1186/1471-2164-15-48, doi:10.1186/1471-2164-15-48. This article has 92 citations and is from a peer-reviewed journal.

4. (pintopinho2024comparativebioinformaticanalysis pages 13-14): Patrícia Pinto-Pinho, João Soares, Pedro Esteves, Rosário Pinto-Leite, Margarida Fardilha, and Bruno Colaço. Comparative bioinformatic analysis of the proteomes of rabbit and human sex chromosomes. Animals, 14:217, Jan 2024. URL: https://doi.org/10.3390/ani14020217, doi:10.3390/ani14020217. This article has 2 citations and is from a peer-reviewed journal.

5. (lopezbigas2008functionalproteindivergence pages 6-7): Nuria Lopez-Bigas, Subhajyoti De, and Sarah A Teichmann. Functional protein divergence in the evolution of homo sapiens. Genome Biology, 9:R33-R33, Feb 2008. URL: https://doi.org/10.1186/gb-2008-9-2-r33, doi:10.1186/gb-2008-9-2-r33. This article has 75 citations and is from a highest quality peer-reviewed journal.

6. (aleksander2023thegeneontology pages 6-6): Suzi A Aleksander, James Balhoff, Seth Carbon, J Michael Cherry, Harold J Drabkin, Dustin Ebert, Marc Feuermann, Pascale Gaudet, Nomi L Harris, David P Hill, Raymond Lee, Huaiyu Mi, Sierra Moxon, Christopher J Mungall, Anushya Muruganugan, Tremayne Mushayahama, Paul W Sternberg, Paul D Thomas, Kimberly Van Auken, Jolene Ramsey, Deborah A Siegele, Rex L Chisholm, Petra Fey, Maria Cristina Aspromonte, Maria Victoria Nugnes, Federica Quaglia, Silvio Tosatto, Michelle Giglio, Suvarna Nadendla, Giulia Antonazzo, Helen Attrill, Gil dos Santos, Steven Marygold, Victor Strelets, Christopher J Tabone, Jim Thurmond, Pinglei Zhou, Saadullah H Ahmed, Praoparn Asanitthong, Diana Luna Buitrago, Meltem N Erdol, Matthew C Gage, Mohamed Ali Kadhum, Kan Yan Chloe Li, Miao Long, Aleksandra Michalak, Angeline Pesala, Armalya Pritazahra, Shirin C C Saverimuttu, Renzhi Su, Kate E Thurlow, Ruth C Lovering, Colin Logie, Snezhana Oliferenko, Judith Blake, Karen Christie, Lori Corbani, Mary E Dolan, Harold J Drabkin, David P Hill, Li Ni, Dmitry Sitnikov, Cynthia Smith, Alayne Cuzick, James Seager, Laurel Cooper, Justin Elser, Pankaj Jaiswal, Parul Gupta, Pankaj Jaiswal, Sushma Naithani, Manuel Lera-Ramirez, Kim Rutherford, Valerie Wood, Jeffrey L De Pons, Melinda R Dwinell, G Thomas Hayman, Mary L Kaldunski, Anne E Kwitek, Stanley J F Laulederkind, Marek A Tutaj, Mahima Vedi, Shur-Jen Wang, Peter D’Eustachio, Lucila Aimo, Kristian Axelsen, Alan Bridge, Nevila Hyka-Nouspikel, Anne Morgat, Suzi A Aleksander, J Michael Cherry, Stacia R Engel, Kalpana Karra, Stuart R Miyasato, Robert S Nash, Marek S Skrzypek, Shuai Weng, Edith D Wong, Erika Bakker, Tanya Z Berardini, Leonore Reiser, Andrea Auchincloss, Kristian Axelsen, Ghislaine Argoud-Puy, Marie-Claude Blatter, Emmanuel Boutet, Lionel Breuza, Alan Bridge, Cristina Casals-Casas, Elisabeth Coudert, Anne Estreicher, Maria Livia Famiglietti, Marc Feuermann, Arnaud Gos, Nadine Gruaz-Gumowski, Chantal Hulo, Nevila Hyka-Nouspikel, Florence Jungo, Philippe Le Mercier, Damien Lieberherr, Patrick Masson, Anne Morgat, Ivo Pedruzzi, Lucille Pourcel, Sylvain Poux, Catherine Rivoire, Shyamala Sundaram, Alex Bateman, Emily Bowler-Barnett, Hema Bye-A-Jee, Paul Denny, Alexandr Ignatchenko, Rizwan Ishtiaq, Antonia Lock, Yvonne Lussi, Michele Magrane, Maria J Martin, Sandra Orchard, Pedro Raposo, Elena Speretta, Nidhi Tyagi, Kate Warner, Rossana Zaru, Alexander D Diehl, Raymond Lee, Juancarlos Chan, Stavros Diamantakis, Daniela Raciti, Magdalena Zarowiecki, Malcolm Fisher, Christina James-Zorn, Virgilio Ponferrada, Aaron Zorn, Sridhar Ramachandran, Leyla Ruzicka, Monte Westerfield, Suzi A Aleksander, James Balhoff, Seth Carbon, J Michael Cherry, Harold J Drabkin, Dustin Ebert, Marc Feuermann, Pascale Gaudet, Nomi L Harris, David P Hill, Raymond Lee, Huaiyu Mi, Sierra Moxon, Christopher J Mungall, Anushya Muruganugan, Tremayne Mushayahama, Paul W Sternberg, Paul D Thomas, Kimberly Van Auken, Jolene Ramsey, Deborah A Siegele, Rex L Chisholm, Petra Fey, Maria Cristina Aspromonte, Maria Victoria Nugnes, Federica Quaglia, Silvio Tosatto, Michelle Giglio, Suvarna Nadendla, Giulia Antonazzo, Helen Attrill, Gil dos Santos, Steven Marygold, Victor Strelets, Christopher J Tabone, Jim Thurmond, Pinglei Zhou, Saadullah H Ahmed, Praoparn Asanitthong, Diana Luna Buitrago, Meltem N Erdol, Matthew C Gage, Mohamed Ali Kadhum, Kan Yan Chloe Li, Miao Long, Aleksandra Michalak, Angeline Pesala, Armalya Pritazahra, Shirin C C Saverimuttu, Renzhi Su, Kate E Thurlow, Ruth C Lovering, Colin Logie, Snezhana Oliferenko, Judith Blake, Karen Christie, Lori Corbani, Mary E Dolan, Harold J Drabkin, David P Hill, Li Ni, Dmitry Sitnikov, Cynthia Smith, Alayne Cuzick, James Seager, Laurel Cooper, Justin Elser, Pankaj Jaiswal, Parul Gupta, Pankaj Jaiswal, Sushma Naithani, Manuel Lera-Ramirez, Kim Rutherford, Valerie Wood, Jeffrey L De Pons, Melinda R Dwinell, G Thomas Hayman, Mary L Kaldunski, Anne E Kwitek, Stanley J F Laulederkind, Marek A Tutaj, Mahima Vedi, Shur-Jen Wang, Peter D’Eustachio, Lucila Aimo, Kristian Axelsen, Alan Bridge, Nevila Hyka-Nouspikel, Anne Morgat, Suzi A Aleksander, J Michael Cherry, Stacia R Engel, Kalpana Karra, Stuart R Miyasato, Robert S Nash, Marek S Skrzypek, Shuai Weng, Edith D Wong, Erika Bakker, Tanya Z Berardini, Leonore Reiser, Andrea Auchincloss, Kristian Axelsen, Ghislaine Argoud-Puy, Marie-Claude Blatter, Emmanuel Boutet, Lionel Breuza, Alan Bridge, Cristina Casals-Casas, Elisabeth Coudert, Anne Estreicher, Maria Livia Famiglietti, Marc Feuermann, Arnaud Gos, Nadine Gruaz-Gumowski, Chantal Hulo, Nevila Hyka-Nouspikel, Florence Jungo, Philippe Le Mercier, Damien Lieberherr, Patrick Masson, Anne Morgat, Ivo Pedruzzi, Lucille Pourcel, Sylvain Poux, Catherine Rivoire, Shyamala Sundaram, Alex Bateman, Emily Bowler-Barnett, Hema Bye-A-Jee, Paul Denny, Alexandr Ignatchenko, Rizwan Ishtiaq, Antonia Lock, Yvonne Lussi, Michele Magrane, Maria J Martin, Sandra Orchard, Pedro Raposo, Elena Speretta, Nidhi Tyagi, Kate Warner, Rossana Zaru, Alexander D Diehl, Raymond Lee, Juancarlos Chan, Stavros Diamantakis, Daniela Raciti, Magdalena Zarowiecki, Malcolm Fisher, Christina James-Zorn, Virgilio Ponferrada, Aaron Zorn, Sridhar Ramachandran, Leyla Ruzicka, and Monte Westerfield. The gene ontology knowledgebase in 2023. Genetics, Mar 2023. URL: https://doi.org/10.1093/genetics/iyad031, doi:10.1093/genetics/iyad031. This article has 1489 citations and is from a domain leading peer-reviewed journal.

Deep Research Report: GDPD2 (human)

Generated using OpenAI Deep Research API

UniProt ID: Q9HCC8
Directory alias: GDPD2

Gene Function and Molecular Mechanisms

GDPD2 (glycerophosphodiester phosphodiesterase domain-containing protein 2), also known as GDE3, encodes an enzyme with glycerophosphoinositol inositolphosphodiesterase activity (EC 3.1.4.43) (lipidmaps.org) (pmc.ncbi.nlm.nih.gov). This enzyme specifically hydrolyzes glycerophosphoinositol (GroPIns) into glycerol and inositol 1-phosphate, and notably does not act on related glycerophosphodiesters such as glycerophosphoinositol-4-phosphate, glycerophosphocholine, -ethanolamine, or -serine (lipidmaps.org) (pmc.ncbi.nlm.nih.gov). GDPD2 functions as an ecto-enzyme, requiring millimolar Ca²⁺ as a cofactor, and its catalytic domain is oriented extracellularly (lipidmaps.org) (pmc.ncbi.nlm.nih.gov). As a result, it hydrolyzes extracellular GroPIns without altering the intracellular pool (lipidmaps.org). A critical arginine residue (Arg-231) in the catalytic GP-PDE domain is required for activity, as mutation of this residue abolishes enzymatic function (pmc.ncbi.nlm.nih.gov). Through its enzymatic action, GDPD2 is thought to modulate signaling pathways involving GroPIns, which has been implicated in cell growth and differentiation signals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consistently, GDPD2 activity has been linked to changes in cell morphology, suggesting downstream effects on cytoskeletal or membrane dynamics (pmc.ncbi.nlm.nih.gov).

Cellular Localization and Subcellular Components

GDPD2 is a multi-pass membrane protein predominantly localized at the plasma membrane (lipidmaps.org). Topology studies indicate that it spans the membrane multiple times, anchoring the protein at the cell surface (lipidmaps.org). The catalytic domain resides on the extracellular side of the membrane, consistent with the finding that glycerophosphoinositol is hydrolyzed in the extracellular medium by overexpressed GDPD2 (lipidmaps.org) (pmc.ncbi.nlm.nih.gov). In addition to the cell surface, GDPD2 has been observed in the cytoplasm associated with the cytoskeleton, co-localizing with actin filaments (lipidmaps.org). This suggests that GDPD2 may concentrate at sites of actin-rich membrane structures (e.g. ruffles or protrusions), potentially linking its enzymatic activity to cytoskeletal remodeling. Indeed, experiments noted GDPD2’s influence on cell shape and morphology (pmc.ncbi.nlm.nih.gov), supporting a role at the interface of the plasma membrane and the actin cytoskeleton. Key Gene Ontology (GO) cellular component terms for GDPD2 include “integral component of membrane” (plasma membrane) and “actin cytoskeleton”, reflecting these localizations (hmdb.ca).

Biological Processes Involvement

GDPD2 is strongly implicated in bone formation and osteoblast differentiation. Its expression and activity are up-regulated during the maturation of osteoblasts (bone-forming cells), and it is considered a marker of osteoblast differentiation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Overexpression of GDPD2 (GDE3) in osteoblastic cells has been shown to promote osteoblast differentiation, evidenced by increased alkaline phosphatase activity and mineralized calcium deposition (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This suggests GDPD2 accelerates the osteogenic program and the growth of bone tissue, aligning with its UniProt annotation that it “accelerates the program of osteoblast differentiation and growth” (www.proteinatlas.org). Conversely, GDPD2 activity appears to modulate cell proliferation; as osteoblasts differentiate, proliferation slows, indicating GDPD2 may help switch cells from a proliferative state to a mature, mineralizing state (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Beyond skeletogenesis, GDPD2’s unique lipid substrate specificity ties it to lipid metabolic processes, particularly the catabolism of glycerophosphoinositol lipids (pmc.ncbi.nlm.nih.gov). By hydrolyzing GroPIns, GDPD2 could influence signaling pathways (GroPIns is known to partake in cell signaling and growth control (pmc.ncbi.nlm.nih.gov)), thus impacting processes like cell growth, differentiation, and possibly apoptosis in certain contexts. Additionally, GDPD2 has been associated with actin cytoskeleton organization, as changes in cell morphology and cytoskeletal arrangement were observed upon altering GDPD2 levels (pmc.ncbi.nlm.nih.gov). This supports a proposed role in actin filament remodeling, which could affect cell migration or shape. Relevant GO terms for processes include “lipid catabolic process”, “osteoblast differentiation”, and “actin cytoskeleton organization”, consistent with current evidence (hmdb.ca) (www.proteinatlas.org).

Disease Associations and Phenotypes

To date, there are no well-established hereditary diseases directly caused by mutations in GDPD2 in humans. GDPD2 is located on the X chromosome (Xq13.1), but no X-linked disorder has been definitively tied to this gene. However, given its role in bone differentiation, researchers have considered that GDPD2 dysfunction might impact bone density or skeletal development. In mice, Gde3 (GDPD2) is highly expressed in osteocytes and late-stage osteoblasts (pmc.ncbi.nlm.nih.gov), suggesting that loss of this enzyme could potentially affect bone formation or turnover; nevertheless, published mouse knockout phenotypes for Gdpd2 have not been prominently reported, implying either a subtle effect or functional compensation by related enzymes. There are some intriguing correlative findings in human data: The Human Protein Atlas reports that GDPD2 RNA is enhanced in certain cancers, such as glioblastoma multiforme, and elevated in some cancer cell lines (e.g. bladder carcinoma cell lines) (www.proteinatlas.org). This cancer-enhanced expression hints at a possible role in tumor biology (perhaps through altering cellular growth or motility), but currently there is no direct evidence linking GDPD2 to oncogenesis or specific cancer phenotypes. Similarly, large-scale genomic studies have not highlighted GDPD2 in common disease contexts, aside from occasional text-mined associations that are not yet experimentally confirmed. In summary, while GDPD2’s importance in bone differentiation is clear, its involvement in human disease remains to be fully determined, and it is a subject for future investigation.

Protein Domains and Structural Features

GDPD2 is a member of the glycerophosphoryl diester phosphodiesterase (GP-PDE) family of enzymes (lipidmaps.org). It contains a single GP-PDE catalytic domain that confers its enzymatic activity of cleaving glycerophosphodiester bonds (lipidmaps.org). Characteristic of this family, GDPD2 has several hydrophobic transmembrane segments near its N-terminus that anchor the protein in the membrane, with computational predictions and experimental data indicating multiple transmembrane passes (multi-pass membrane protein architecture) (lipidmaps.org). The N-terminus likely includes a signal peptide or leader sequence targeting the protein to the secretory pathway, ensuring the catalytic domain is presented in the luminal/extracellular space (lipidmaps.org). The active site of the GP-PDE domain requires divalent cations for catalysis – notably Ca²⁺ acts as a cofactor to facilitate bond cleavage (lipidmaps.org). An invariant arginine (Arg-231 in human GDPD2) within the domain is critical for catalysis (pmc.ncbi.nlm.nih.gov), reflecting a conserved active-site motif important for substrate binding or phosphodiester bond breakage. Three isoforms of GDPD2 have been reported due to alternative splicing (590 amino acids in isoform 1; 539 aa in isoform 2; 460 aa in isoform 3) (lipidmaps.org). Isoform 1 (590 aa) is the full-length, primary form, while isoforms 2 and 3 lack certain internal segments (their existence is predicted from transcript data and not experimentally confirmed) (lipidmaps.org) (lipidmaps.org). These shorter isoforms may lack some transmembrane regions or functional elements, potentially altering localization or activity, although their biological significance remains unclear. Metal-binding sites (for Ca²⁺) and conserved catalytic residues within the GP-PDE domain define the molecular function of GDPD2 (lipidmaps.org). No full crystallographic structure is yet available, but an AlphaFold predicted structure exists (based on homology modeling), which confirms the globular ectodomain and transmembrane helices consistent with the proposed topology. In summary, GDPD2’s structure comprises a membrane-anchored ecto-enzyme domain belonging to a highly conserved phosphodiesterase family, with features supporting its role in lipid substrate recognition and hydrolysis.

Expression Patterns and Regulation

GDPD2 shows a tissue-specific expression pattern that aligns with its functional role in bone. It is most prominently expressed in osteogenic lineage cells – studies in mice have shown Gde3 (GDPD2) mRNA is low in undifferentiated osteoblasts but significantly up-regulated in mature osteoblasts and osteocytes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This developmental regulation suggests that transcription of GDPD2 is controlled by osteogenic differentiation programs (potentially downstream of bone-specific transcription factors or signaling pathways that drive late-stage differentiation). In humans, RNA profiling indicates that GDPD2 is expressed in a variety of tissues at moderate levels, with the highest expression noted in bone marrow, osteoblasts, and possibly certain epithelial tissues (one analysis clusters GDPD2 with genes in squamous epithelial/keratinization programs) (www.proteinatlas.org). The Human Protein Atlas classifies GDPD2 as “tissue enhanced” in bone-related tissues, and interestingly also reports elevated expression in skin/keratinocytes and cervix (which might relate to the squamous differentiation cluster) – though these data are primarily transcript-based. At the cellular level, GDPD2 protein has been detected in the cytoplasm and membrane of osteoblastic cells. Regulation of GDPD2 expression is not fully elucidated, but given its upregulation with differentiation, it may be controlled by factors like bone morphogenetic proteins (BMPs) or other osteogenic signals. Bioinformatic promoter analyses (if any) have not been highlighted in literature, but Runx2, a master osteoblast transcription factor, could be a candidate regulator. Additionally, GDPD2 has multiple mRNA splice variants (www.proteinatlas.org), hinting at post-transcriptional regulation or tissue-specific isoform expression. There is no evidence that GDPD2 is inducible by acute stimuli (e.g., calcium, hormones) in the short term, but its expression pattern suggests regulation is tied to developmental and differentiation cues. In summary, GDPD2 is expressed broadly at low-to-moderate levels, with notable enrichment in bone-forming cells, and its gene expression is tightly linked to the differentiation status of cells. This pattern underscores its role in specialized biological contexts (bone maturation and possibly epithelial differentiation).

Evolutionary Conservation

GDPD2 is evolutionarily conserved across vertebrates and is a part of an ancient enzyme family present even in bacteria. The GP-PDE enzyme family (glycerophosphodiester phosphodiesterases) was first characterized in bacteria and later identified in mammals (pmc.ncbi.nlm.nih.gov), indicating that organisms from prokaryotes to humans utilize related mechanisms to catabolize glycerophosphodiesters. Human GDPD2 shares significant sequence homology with its mammalian orthologs: for example, the mouse Gdpd2 (Gde3) protein is highly similar in sequence and function (pmc.ncbi.nlm.nih.gov). GDPD2 orthologs are found in all placental mammals examined, as well as in marsupials and likely other vertebrates (e.g., birds and reptiles have GDPD2-like genes, given the presence of a GDPD2 gene in turtle genome data (www.ncbi.nlm.nih.gov)). Within primates, GDPD2 is well conserved (chimpanzee GDPD2 is ~99% identical to human, as expected from its essential functional role). The conservation extends to amino acids critical for catalytic activity – for instance, the Arg residue essential for activity and metal-binding motifs in the GP-PDE domain are conserved across species (pmc.ncbi.nlm.nih.gov). This high degree of conservation suggests strong purifying selection, implying GDPD2’s function in glycerophosphoinositol metabolism is biologically important across species. In contrast, lower eukaryotes like yeast have analogous glycerophosphodiester phosphodiesterases (e.g., yeast Git1 and others) but these are structurally distinct glycerol-3-phosphate transporters or enzymes, not one-to-one orthologs. Among the seven mammalian GDE family members (GDE1–GDE7), GDPD2 (GDE3) has a specific niche in bone tissue, whereas other family members have diverged to fulfill roles in nervous system development (GDE2), ubiquitous signaling (GDE1), etc. (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The presence of this enzyme family in diverse organisms underlines its fundamental role in lipid metabolism. Thus, GDPD2 is an evolutionarily conserved gene, particularly within vertebrates, reflecting the conserved nature of glycerophosphoinositol metabolism and its importance in cellular physiology.

Key Experimental Evidence and Literature

Multiple studies have established GDPD2’s functions and characteristics. A cornerstone study by Corda et al. (2009) characterized mouse GDE3 (GDPD2) as a glycerophosphoinositol-specific phosphodiesterase and demonstrated its role in osteoblast differentiation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This study provided direct evidence of GDPD2’s substrate specificity (cleaving GroPIns but not related lipids) and showed that overexpressing GDE3 in osteoblasts increased differentiation markers (alkaline phosphatase, mineralization) (pmc.ncbi.nlm.nih.gov). It also revealed the requirement of Ca²⁺ for activity and an extracellular orientation of the catalytic domain (pmc.ncbi.nlm.nih.gov). Another key piece of evidence from the same work was the identification of Arg-231 as critical for catalysis via site-directed mutagenesis (pmc.ncbi.nlm.nih.gov). Following this, a review by Yanaka (2007) surveyed the mammalian glycerophosphodiester phosphodiesterase family, noting GDE3’s high expression in osteocytes and suggesting its role as a differentiation marker (pmc.ncbi.nlm.nih.gov). A 2013 Frontiers in Immunology review by Patrussi et al. further highlighted that GDE1 and GDE3 are ecto-enzymes that hydrolyze extracellular GroPIns, and specifically described GDE3 as predominantly expressed in bone cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This review also underscored the idea that GroPIns can act as a signaling molecule in cell proliferation and that GDE3’s activity (producing inositol-1-phosphate and glycerol) might modulate such signals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The Human Protein Atlas provides expression data, showing GDPD2’s enrichment in osteoblastic cells and certain cancers (www.proteinatlas.org). Lastly, the UniProt database (Q9HCC8) and NCBI RefSeq provide curated summaries corroborating these findings, noting GDPD2’s enzymatic function, localization, and “by similarity” inferred roles in actin cytoskeleton remodeling (www.proteinatlas.org) (lipidmaps.org). Together, these literature sources form a coherent picture: GDPD2 (GDE3) is an ecto-phosphodiesterase with a specialized role in bone cell differentiation and a unique substrate specificity, supported by both experimental enzymology and cell biology evidence. Key GO annotations drawn from this body of work include glycerophosphoinositol glycerophosphodiester phosphodiesterase activity, integral component of plasma membrane, actin cytoskeleton, osteoblast differentiation, and lipid metabolic process, each backed by experimental findings (hmdb.ca) (www.proteinatlas.org). The accumulating research thus provides a solid foundation for Gene Ontology curation of GDPD2, linking its molecular function to cellular context and biological outcomes.

References: Primary literature and databases were used to compile this report, including functional enzymology studies (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), reviews on lipid signaling (pmc.ncbi.nlm.nih.gov), and curated database annotations from UniProt and NCBI (lipidmaps.org) (www.proteinatlas.org). These sources ensure that each aspect of GDPD2 – from biochemical activity to physiological role – is documented with experimental evidence appropriate for GO annotation.